TEJNAKSH HEALTHCARE LIMITED

Regd. Add. : Lion Tarachand Bapa Hospital, Lion Tarachand Bapa Hospital Marg, Sion (W), Mumbai - 22
CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com
Website : www.tejnaksh.com | Tel No. : 022 – 2404 4983/ 2404 4984

15.09.2020

To,
BSE Limited
PhirozeJeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001

Dear Sir/Madam,

Scrip Code: 539428

Sub: Submission of Un-Audited Financial Results (Standalone & Consolidated) for the Quarter ended on 30th June, 2020

Please find the enclosed herewith Unaudited Financial Results (Standalone & Consolidated) for the Quarter ended on 30th June, 2020 along with Limited Review Report thereon approved by the Board of Directors of the Company at its Meeting held on Tuesday, 15th September, 2020 at Lion TarachandBapa Hospital, Lion TarachandBapa Hospital Marg, Sion - West, Mumbai – 400 033 at 1.00 P.M., in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information and record.

Thanking you.
For Tejnaksh Healthcare Limited

Rawandale

Tejnaksh Healthcare Limited MUMBAI

Dr. Ashish V. Rawandale
Managing Director
DIN:- 02005733

Limited Review Report on quarterly and year to date unaudited Standalone Ind AS Financial Results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Tejnaksh Healthcare Limited [CIN : L85100MH2008PLC179034]
Mumbai

1. We have reviewed the accompanying statement of standalone unaudited financial results of Tejnaksh Healthcare Limited ("the Company") for the quarter ended June 30, 2020 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accow1tants of India. This standard requires that we plan and perfom1 the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

P.D.DALAL & CO. Chartered Accountants

102, B Wing, Lake Florence, Phase I, Adi Shankaracharya Marg, Powai,
Mumbai - 400 076 Maharashtra India Email : auditpdd@gmail.com

5.Emphasis of Matter

We draw attention to Note 5 of the Statement, which describes the circumstances arising due to COVID-19, the uncertainties associated with its nature and duration and the consequential impact of the same on the financial results of the company.

Our conclusion on the statement is not modified in respect or the above matter.

For P.D.Dalal & Co.
Chartered Accountants
ICAI Firm Registration No.102047W

(Aashish S. Kakaria)
Partner
Membership No.102915

Mumbai
15th September, 2020
UDIN : 20102915AAAADX7594

102, B Wing, Lake Florence, Phase I, Adi Shankaracharya Marg, Powai, Mumbai - 400 076 Maharashtra India Email : auditpdd@gmail.com

TEJNAKSH HEALTHCARE LIMITED

Regd. Add. : Lion Tarachand Bapa Hospital, Lion Tarachand Bapa Hospital Marg, Sion (W), Mumbai - 22
CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com
Website : www.tejnaksh.com | Tel No. : 022 – 2404 4983/ 2404 4984

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE, 2020

Amount Rs.Lacs

Sr.No.	Particulars	Quarter Ended			Year Ended
		June 30,2020	March 31,2020	June 30,2019	March 31,2020
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	**REVENUE**				
(a)	Revenue from operations (net)	123.83	232.45	307.00	1,113.77
(b)	Other income	2.45	22.10	13.60	84.38
	Total Revenue (I)	**126.29**	**254.55**	**320.60**	**1,198.15**
2	**EXPENSES**				
(a)	Purchases of stock-in-trade	6.91	7.61	17.73	53.04
(b)	Changes in inventories of Stock-in-Trade	(3.04)	14.10	5.85	12.85
(c)	Employee benefits expense	17.32	44.82	43.40	163.80
(d)	Finance costs	14.23	24.50	19.44	79.52
(e)	Depreciation and amortization expense	15.30	15.40	13.89	58.59
(f)	Other expenses	54.30	145.03	119.94	564.28
	Total Expenses (II)	**105.01**	**251.47**	**220.25**	**932.09**
3	**Profit before tax (I) - (II)**	**21.28**	**3.08**	**100.35**	**266.06**
4	**Tax expense:**				
(a)	Current tax	2.91	4.34	24.25	61.38
(b)	Adjustment of tax relating to earlier periods				
(c)	Deferred tax	3.01	6.47	3.65	12.32
	Total Tax Expenses	5.92	10.82	27.90	73.71
5	**Profit for the year**	**15.36**	**(7.74)**	**72.45**	**192.35**
6	**OTHER COMPREHENSIVE INCOME**				
	A. Other Comprehensive income not to be reclassified to profit and loss in subsequent periods:	-	-	-	-
	B. Other Comprehensive income to be reclassified to profit and loss in subsequent periods:	-	-	-	-
	Other Comprehensive income for the year, net of tax	-	-	-	-
	TOTAL COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX	15.36	(7.74)	72.45	192.35
7	**Paid up Equity Share Capital (Face value Rs 10/-**	101.57	101.57	101.57	101.57
8	**Other Equity excluding revaluation reserve as per Balance Sheet**				-
9	**Basic and Diluted earnings per share (INR)**	0.15	(0.08)	0.71	1.89

Notes:

1 The Statement of unaudited standalone financial results ('the Statement') of Tejnaksh Health ('the Company') for the quarter ended June 30, 2020 has been reviewed by the Audit Risk and Compliance Committee and approved by the Board of Directors on September 15, 2020. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.

Tejnaksh Healthcare Limited MUMBAI

2 The Statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

3 The Company's operating segment is 'Medical and Healthcare Services. Since the Company has a single operating segment. disclosure pertaining to segments as per Regulation 33(1)(c) read with clause (L) of Part A of Schedule IV of the SEBI Regulations is not applicable.

4 The figures for the quarter ended March 31, 2020 are the balancing figures between audited figures In respect of the full financial year for 2019-20 and published unaudited year to date figures up to the third quarter ended December 31, 2019.

5 On March 11 , 2020, the World Health Organization declared COVID-19 a global pandemic and suggested guidelines for containment and mitigation worldwide. This has impacted the operations of the Company during the quarter ended June 30, 2020. As at June 30, 2020, the Management has used internal and external sources of information upto the date of approval of these financial results in determining the impact of the COVID-19 pandemic. The Management has used the principles of prudence in developing estimates, assumptions, exercising judgements and performing sensitivity analysis. The eventual outcome of the impact of the pandemic may be different from that estimated as on the date of approval of these financial results. However the impact assessment of COVID-19 is a continuous process, given the uncertainties associated with its nature and duration. The Company will continue to monitor any material changes to future economic conditions and the consequent impact on its business, if any, and any significant impact of these changes would be recognized in the financial results as and when these material changes to economic conditions arise.

For and on behalf of board of Directors
Tejnaksh Healthcare Limited

(Dr. A.V. Rawandale)
Managing Director
DIN: 02005733

Tejnaksh Healthcare Limited MUMBAI

Place: Mumbai
Date: 15.09.2020

Limited Review Report on quarterly and year to date unaudited Consolidated Ind AS Financial Results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Tejnaksh Healthcare Limited [CIN : L85100MH2008PLC179034]
Mumbai

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of Tejnaksh Healthcare Limited ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group"), for the quarter ended June 30, 2020 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2.This Statement, which is the responsibility of the Parent's Management and approved by the Parents Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34. (Ind AS 34) 'Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3.We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410. Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and performthe review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial infom1ation consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMDI/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4.The Statement includes results of the Holding Company- Tejnaksh Healthcare Limited and its subsidiary Company - TejVedaant Healthcare Private Limited.

5.The accompanying unaudited consolidated financial results includes unaudited interim financial results and other unaudited financial information in respect of its subsidiary which have been approved and furnished to us by the management. Our conclusion on the Statement is not modified in respect of the above matter.

P.D.DALAL & CO. Chartered Accountants

102, B Wing, Lake Florence, Phase I, Adi Shankaracharya Marg, Powai, Mumbai -.400 076 Maharashtra India Email : auditpdd@gmail.com

6. Based on our review conducted and procedures performed as stated in paragraph 3 above,nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed. or that it contains any material misstatement.

7.Emphasis of Matter

We draw attention to Note 5 of the Statement, which describes the circumstances arising due to COVID-19, the uncertainties associated with its nature and duration and the consequential impact of the same on the financial results of the Group.

Our conclusion on the Statement is not modified in respect or the above matter.

For P.D.Dalal & Co.
Chartered Accountants
ICAI Firm Registration No.102047W

Akakaria

(Aashish S. Kakaria)
Partner
Membership No.102915

P.D. DALAL & CO. Chartered Accountants

Mumbai
15th September, 2020
UDIN : 20102915AAAADY7270

102, B Wing, Lake Florence, Phase I, Adi Shankaracharya Marg, Powai, Mumbai - 400 076 Maharashtra India Email : auditpdd@gmail.com

TEJNAKSH HEALTHCARE LIMITED

Regd. Add. : Lion Tarachand Bapa Hospital, Lion Tarachand Bapa Hospital Marg, Sion (W), Mumbai - 22
CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com
Website : www.tejnaksh.com | Tel No. : 022 – 2404 4983/ 2404 4984

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE, 2020

Amount Rs.Lacs

Sr.No.	Particulars	Quarter Ended			Year Ended
		June 30,2020	March 31,2020	June 30,2019	March 31,2020
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	**REVENUE**				
(a)	Revenue from operations (net)	158.45	354.69	445.81	1,675.65
(b)	Other income	1.84	15.86	10.52	70.11
	Total Revenue (I)	**160.29**	**370.55**	**456.33**	**1,745.76**
2	**EXPENSES**				
(a)	Purchases of stock-in-trade	11.28	15.75	35.21	109.75
(b)	Changes in inventories of Stock-in-Trade	(4.74)	15.57	8.32	19.97
(c)	Employee benefits expense	24.33	67.21	65.50	255.42
(d)	Finance costs	13.37	19.79	19.86	76.10
(e)	Depreciation and amortization expense	17.01	17.16	15.54	65.44
(f)	Other expenses	88.83	228.00	208.52	922.51
	Total Expenses (II)	**150.08**	**363.48**	**352.95**	**1,449.20**
3	**Profit before tax (I) - (II)**	**10.21**	**7.07**	**103.38**	**296.55**
4	**Tax expense:**				
(a)	Current tax	2.91	5.75	24.83	69.30
(b)	Adjustment of tax relating to earlier periods				-
(c)	Deferred tax	2.85	6.33	3.91	12.69
	Total Tax Expenses	5.76	12.08	28.74	81.99
5	**Profit for the year**	**4.45**	**(5.01)**	**74.64**	**214.56**
6	**OTHER COMPREHENSIVE INCOME**				
	A. Other Comprehensive income not to be reclassified to profit and loss in subsequent periods:		-	-	-
	B. Other Comprehensive income to be reclassified to profit and loss in subsequent periods:		-	-	-
	Other Comprehensive income for the year, net of tax		-	-	-
	TOTAL COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX	4.45	(5.01)	74.64	214.56
7	**Profit for the year attributable to:**				
	Equity holders of the parent	7.18	(5.69)	74.09	209.01
	Non-controlling interests	(2.73)	0.68	0.55	5.55
8	**Total comprehensive income for the year attributable to:**				
	Equity holders of the parent	7.18	(5.69)	74.09	209.01
	Non-controlling interests	(2.73)	0.68	0.55	5.55
9	**Paid up Equity Share Capital (Face value Rs 10/- each.)**	101.57	101.57	101.57	101.57
10	**Other Equity excluding revaluation reserve as per Balance Sheet**				-
11	**Basic and Diluted earnings per share (INR)**	0.04	(0.05)	0.73	2.06

Notes:

1 The Statement of unaudited consolidated financial results ('the Statement') of Tejnaksh Health (the'Parent'/ 'Group') and its subsidiaries (together referred to as the 'Group') for the quarter ended June 30, 2020 has been reviewed by the Audit Risk and Compliance Committee and approved by the Board of Directors on September 15, 2020. The Statutory Auditors of the Group have carried out a Limited Review of the aforesaid results.

Tejnaksh Healthcare Limited MUMBAI

2 The Statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

3 The Groups's operating segment is 'Medical and Healthcare Services. Since the Group has a single operating segment. disclosure pertaining to segments as per Regulation 33(1)(c) read with clause (L) of Part A of Schedule IV of the SEBI Regulations is not applicable.

4 The figures for the quarter ended March 31, 2020 are the balancing figures between audited figures In respect of the full financial year for 2019-20 and published unaudited year to date figures up to the third quarter ended December 31, 2019.

5 On March 11, 2020, the World Health Organization declared COVID-19 a global pandemic and suggested guidelines for containment and mitigation worldwide. This has impacted the operations of the Group during the quarter ended June 30, 2020. As at June 30, 2020, the Management has used internal and external sources of information upto the date of approval of these financial results in determining the impact of the COVID-19 pandemic. The Management has used the principles of prudence in developing estimates, assumptions, exercising judgements and performing sensitivity analysis. The eventual outcome of the impact of the pandemic may be different from that estimated as on the date of approval of these financial results. However the impact assessment of COVID-19 is a continuous process, given the uncertainties associated with its nature and duration. The Group will continue to monitor any material changes to future economic conditions and the consequent impact on its business, if any, and any significant impact of these changes would be recognized in the financial results as and when these material changes to economic conditions arise.

For and on behalf of board of Directors
Tejnaksh Healthcare Limited

(Dr. A.V. Rawandale)
Managing Director
DIN: 02005733

Tejnaksh Healthcare Limited MUMBAI

Place: Mumbai
Date: 15.09.2020